Glucocorticoids cause osteoporosis through several simultaneous mechanisms: they kill the cells that build new bone, ramp up the cells that break bone down, block calcium absorption in the gut, suppress sex hormones, and weaken muscles in ways that increase fall risk. Fracture risk rises even at daily doses as low as 2.5 mg of prednisone, and bone loss can begin within the first month of treatment.
Bone-Building Cells Are Suppressed and Killed
The most direct damage glucocorticoids do is to osteoblasts, the cells responsible for forming new bone. Glucocorticoids limit both the function and the lifespan of these cells, which ultimately means less new bone is laid down to replace what’s naturally lost.
At the cellular level, glucocorticoids halt the growth cycle of osteoblast precursors. They dial down the proteins that push cells through division while turning up the proteins that act as brakes on that process. The result is that fewer new osteoblasts are produced in the first place. On top of that, glucocorticoids trigger premature death (apoptosis) in mature osteoblasts and in osteocytes, the long-lived cells embedded within bone that act as its internal sensing network. When osteocytes die, bone loses its ability to detect microdamage and signal for repairs.
Animal studies confirm this is a direct effect: when researchers blocked glucocorticoid signaling specifically inside osteoblasts using an enzyme that inactivates the drug before it can act, osteoblast death was prevented and bone formation stayed intact.
Bone-Destroying Cells Become Overactive
While bone formation slows, bone breakdown accelerates. Glucocorticoids tip the balance of a signaling system that controls osteoclasts, the cells that dissolve old bone. Normally, osteoblasts produce two opposing signals: RANKL, which activates osteoclasts, and OPG, a decoy molecule that blocks RANKL and keeps osteoclast activity in check.
Glucocorticoids push this ratio in the wrong direction. They increase RANKL production while decreasing OPG. The glucocorticoid receptor binds directly to the RANKL gene’s promoter region, physically driving up its activity. With more RANKL and less OPG circulating, osteoclast formation increases and bone is broken down faster than it can be rebuilt. This imbalance is one of the central drivers of glucocorticoid-induced osteoporosis.
Calcium Absorption Drops
Healthy bones depend on a steady supply of calcium, and glucocorticoids interfere with that supply at two points. In the gut, they suppress active calcium transport in the small intestine, partly by reducing the activity of enzymes involved in moving calcium across the intestinal lining. In the kidneys, they increase calcium excretion, meaning more calcium is lost through urine.
Glucocorticoids also lower blood levels of the most active form of vitamin D (1,25-dihydroxyvitamin D3), the hormone that drives intestinal calcium absorption. In children on long-term glucocorticoid therapy, levels of this vitamin D metabolite drop in proportion to the steroid dose, and this reduction correlates with measurable loss of bone mineral content. The net effect is a calcium deficit that forces the body to pull more calcium from bone to maintain blood levels, compounding the direct cellular damage already underway.
Sex Hormones and Growth Factors Decline
Glucocorticoids suppress the body’s production of sex hormones, including estrogen and testosterone, both of which are protective for bone. This drug-induced hypogonadism removes a key brake on bone loss. Estrogen in particular slows osteoclast activity, so when levels fall, resorption accelerates further.
Growth hormone and insulin-like growth factor 1 (IGF-1) also decline during glucocorticoid therapy. IGF-1 normally stimulates osteoblast activity and bone formation. Its reduction adds another layer to the suppression of new bone growth, on top of the direct damage glucocorticoids do to osteoblasts themselves.
Muscle Weakness Increases Fall Risk
Bone loss alone doesn’t cause fractures. Falls do. Glucocorticoids cause a distinct pattern of muscle wasting, particularly around the hips and shoulders, that increases fall frequency. This steroid-induced muscle weakness, or myopathy, compounds the skeletal fragility by making fractures more likely to actually happen. Researchers describe the combined deterioration of both bone and muscle as the reason glucocorticoid users have such a pronounced increase in fracture rates compared to people with similar bone density from other causes.
How Quickly Bone Loss Occurs
The speed of glucocorticoid-induced bone loss catches many people off guard. Fracture risk increases even within the first month of treatment, before significant changes in bone density would show up on a scan. This early vulnerability is thought to reflect changes in bone quality, including osteocyte death and disrupted repair signaling, rather than just the total amount of bone present.
Bone density loss is fastest in the first 3 to 6 months, then continues at a slower but steady pace with ongoing use. Even daily doses as low as 2.5 mg of prednisone carry a statistically significant increase in fracture risk. Current guidelines from the American College of Rheumatology recommend fracture risk assessment as soon as possible after starting glucocorticoids for anyone expected to take them for more than 3 months, including bone density testing and, for people 40 and older, a formal fracture risk calculation.
Why the Damage Is Partially Reversible
Because much of glucocorticoid-induced osteoporosis stems from active suppression of bone formation rather than permanent structural destruction, some recovery is possible after stopping the drug. Osteoblast function can resume, calcium balance can normalize, and sex hormone levels can recover. However, the osteocytes that died during treatment are not replaced quickly, and any fractures that occurred are permanent events. The degree of recovery depends on how long the treatment lasted, the dose used, and whether protective treatment was started early. For people at moderate to high fracture risk, medications that either slow bone breakdown or actively stimulate new bone formation are recommended alongside glucocorticoid therapy rather than waiting until damage is visible on a scan.